^
Association details:
| Biomarker: | ALK positive |
|---|---|
| Cancer: | Neuroendocrine Tumor |
| Drug: | Alecensa (alectinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Chugai’s Alecensa Approved in Taiwan as an Adjuvant Treatment for Early Stage ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Excerpt:
Chugai Pharmaceutical Co., Ltd...Taiwan Food and Drug Administration (TFDA) for Chugai’s Alecensa® (alectinib) as an adjuvant treatment following tumor resection (tumors ≥ 4 cm or node positive) for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), on August 1, 2024.
Source:
Title:
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
Excerpt:
...- Histologically confirmed ALK-positive locally-advanced or metastatic solid tumor excluding lung cancer...
Trial ID:
Source:
Title:
A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib
Published date:
02/03/2022
Excerpt:
The patient was started on alectinib, an ALK inhibitor, because of disease progression despite chemotherapy…..Her bone metastases have shown partial response as per RECIST radiographic criteria on a dose of alectinib of 450 mg twice daily alternated with 300 mg twice daily...our patient was treated with adjuvant cisplatin–etoposide doublet chemotherapy based on the LCNEC diagnosis. This was followed by subsequent treatment with alectinib for the newly developed bony metastasis, with an ongoing partial response....As the bone metastases that were confirmed as metastatic ALK‐positive LCNEC showed a partial response with alectinib, we can speculate that the LCNEC component had responded in this case.
DOI:
. https://doi.org/10.3390/curroncol29020072
